Quick Answer
REGENERON PHARMACEUTICALS, INC. reported R&D Expense of $5.85 billion for fiscal year 2025.
REGENERON PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $5.85B | +14.0% |
| 2024 | $5.13B | +15.6% |
| 2023 | $4.44B | +23.6% |
| 2022 | $3.59B | +25.6% |
| 2021 | $2.86B | +8.1% |
| 2020 | $2.65B | +8.0% |
| 2019 | $2.45B | +66.8% |
| 2018 | $1.47B | -29.2% |
| 2017 | $2.08B | +1.1% |
| 2016 | $2.05B | +26.6% |
| 2015 | $1.62B | +27.5% |
| 2014 | $1.27B | +47.8% |
| 2013 | $859.95M | +37.5% |
| 2012 | $625.55M | +18.1% |
| 2011 | $529.51M | +8.2% |
| 2010 | $489.25M | +22.7% |
| 2009 | $398.76M | +45.1% |
| 2008 | $274.90M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.48B | +16.0% | +3.7% |
| June 30, 2025 | $1.42B | +18.5% | +7.1% |
| March 31, 2025 | $1.33B | +6.3% | +4.4% |
| September 30, 2024 | $1.27B | +18.2% | +6.0% |
| June 30, 2024 | $1.20B | +10.6% | -3.9% |
| March 31, 2024 | $1.25B | +13.4% | +16.1% |
| September 30, 2023 | $1.08B | +18.0% | -0.9% |
| June 30, 2023 | $1.09B | +36.6% | -1.4% |
- REGENERON PHARMACEUTICALS, INC. showed an increase of +14.0% in R&D Expense compared to the prior fiscal year.
- Over the 2008–2025 period, REGENERON PHARMACEUTICALS, INC.’s r&d expense has grown by 2028.1% (from $274.90 million to $5.85 billion).
- The most recent figure is from REGENERON PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: